dapsone has been researched along with Aortic Arteritis, Giant Cell in 21 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Authors describe three cases of agranulocytosis in patients with giant cell (temporal) arterities treated with Dapsone and corticosteroids." | 8.77 | [Agranulocytosis caused by dapsone. Apropos of 3 cases. Review of the literature]. ( Bordessoule, D; Cransac, M; Fourgnaud-Gaillard, S; Liozon, E; Liozon, F; Rousset, H; Vidal, E; Weinbreck, P, 1988) |
| "The authors report 8 cases of Horton's disease and/or polymyalgia rheumatica treated with prednisone with an initially favourable result." | 7.67 | [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica]. ( Celton, H; Doury, P; Eulry, F; Fabresse, FX; Larroque, P; Pattin, S, 1984) |
| " Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection." | 6.50 | Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. ( Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014) |
| "Authors describe three cases of agranulocytosis in patients with giant cell (temporal) arterities treated with Dapsone and corticosteroids." | 4.77 | [Agranulocytosis caused by dapsone. Apropos of 3 cases. Review of the literature]. ( Bordessoule, D; Cransac, M; Fourgnaud-Gaillard, S; Liozon, E; Liozon, F; Rousset, H; Vidal, E; Weinbreck, P, 1988) |
| "The authors report 8 cases of Horton's disease and/or polymyalgia rheumatica treated with prednisone with an initially favourable result." | 3.67 | [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica]. ( Celton, H; Doury, P; Eulry, F; Fabresse, FX; Larroque, P; Pattin, S, 1984) |
| " Studies included were trials in which: (1) the participants were classified as having GCA by the 1990 ACR criteria or biopsy proven disease; (2) parallel-group randomised control of at least 16 weeks duration had been conducted with at least 20 participants; (3) the design included either alternative adjunct immunosuppressant regimens, alternative GCs dosing or routes of administration; and (4) outcome data was included on either relapse rates or rates of infection." | 2.50 | Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis. ( Loke, YK; MacGregor, AJ; Watts, RA; Yates, M, 2014) |
| "Giant cell arteritis is a medium- and large-vessel vasculitis, the most prevalent systemic vasculitis in subjects over age 60." | 2.44 | [Giant cell arteritis]. ( Liozon, E; Ly, K, 2008) |
| " We describe 3 such patients, and our experience in tapering their steroid dosage with the use of dapsone or methotrexate." | 2.39 | Steroid-sparing medications in temporal arteritis--report of three cases and review of 174 reported patients. ( Nesher, G; Sonnenblick, M, 1994) |
| "The authors report two cases of Horton's disease and one case of rhizomelic pseudopolyarthritis treated initially with delta-cortisone with a very rapid favourable result." | 1.27 | [Value of dapsone in the treatment of Horton's disease and rhizomelic pseudopolyarthritis]. ( Doury, P; Eulry, F; Masson, C; Maurel, C; Pattin, S; Tabaraud, F, 1983) |
| " Nineteen patients had ocular manifestations of giant cell arteritis always from the onset, except for a fall in visual acuity; 26 relapses were observed in 18 patients, either during reduction of steroid dosage (21 cases) or after withdrawal (5 cases)." | 1.27 | [Prognosis of treated temporal arteritis. Retrospective study of 87 cases]. ( Alcalay, M; Becq-Giraudon, B; Boissonnot, L; Bontoux, D; Gil, R; Gouet, D; Le Berre, D; Lefevre, JP; Maréchaud, R; Risse, JF, 1986) |
| " A daily dosage of 75 to 100 mg would seem to provide a good compromise between the anti-inflammatory and haemolytic effects." | 1.27 | [Disulon in the treatment of Horton's disease. Experience with 20 patients]. ( Bonnetblanc, JM; Bordessoule, D; Liozon, F; Loustaud, V; Michel, JP; Vidal, E; Weinbreck, P, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (61.90) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yates, M | 1 |
| Loke, YK | 1 |
| Watts, RA | 1 |
| MacGregor, AJ | 1 |
| Ly, KH | 1 |
| Dalmay, F | 1 |
| Gondran, G | 1 |
| Palat, S | 1 |
| Bezanahary, H | 1 |
| Cypierre, A | 1 |
| Fauchais, AL | 1 |
| Liozon, E | 4 |
| Ly, K | 1 |
| Doury, P | 5 |
| Pattin, S | 4 |
| Eulry, F | 4 |
| Maurel, C | 2 |
| Masson, C | 2 |
| Tabaraud, F | 2 |
| Liozon, F | 4 |
| Vidal, E | 4 |
| Bonnetblanc, JM | 2 |
| Michel, JP | 2 |
| Bordessoule, D | 3 |
| Gasparini, M | 1 |
| Fabresse, FX | 1 |
| Celton, H | 1 |
| Larroque, P | 1 |
| Thabaut, A | 1 |
| Nesher, G | 1 |
| Sonnenblick, M | 1 |
| Boutros-Toni, F | 1 |
| Gaches, F | 1 |
| Loustaud-Ratti, V | 1 |
| Berdah, JF | 1 |
| Pesce, A | 1 |
| Taillan, B | 1 |
| Vinti, H | 1 |
| Rosenthal, E | 1 |
| Garnier, G | 1 |
| Cassuto, JP | 1 |
| Solau-Gervais, E | 1 |
| Flipo, RM | 1 |
| Lons, T | 1 |
| Richardet, JP | 1 |
| Machayekhi, JP | 1 |
| Dalbergue, B | 1 |
| Trinchet, JC | 1 |
| Demaziere, A | 1 |
| Gouet, D | 1 |
| Maréchaud, R | 1 |
| Le Berre, D | 1 |
| Alcalay, M | 1 |
| Becq-Giraudon, B | 1 |
| Boissonnot, L | 1 |
| Bontoux, D | 1 |
| Gil, R | 1 |
| Lefevre, JP | 1 |
| Risse, JF | 1 |
| Fourgnaud-Gaillard, S | 1 |
| Rousset, H | 1 |
| Weinbreck, P | 2 |
| Cransac, M | 1 |
| Boesen, P | 1 |
| Dideriksen, K | 1 |
| Stentoft, J | 1 |
| Jensen, MK | 1 |
| Reinitz, E | 1 |
| Aversa, A | 1 |
| Loustaud, V | 1 |
6 reviews available for dapsone and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: meta-analysis.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dap | 2014 |
[Giant cell arteritis].
Topics: Adrenal Cortex Hormones; Aged, 80 and over; Anti-Infective Agents; Biopsy; Blood Sedimentation; C-Re | 2008 |
[Therapy of polymyalgia rheumatica].
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anti-Inflammatory Agents; Benzodiazepines; Benzothiadiaz | 1984 |
Steroid-sparing medications in temporal arteritis--report of three cases and review of 174 reported patients.
Topics: Aged; Aged, 80 and over; Dapsone; Female; Giant Cell Arteritis; Humans; Methotrexate; Prednisone | 1994 |
[Clinical course of Horton disease. Apropos of 42 cured patients].
Topics: Aged; Aged, 80 and over; Dapsone; Female; Giant Cell Arteritis; Humans; Male; Middle Aged; Prednison | 1994 |
[Agranulocytosis caused by dapsone. Apropos of 3 cases. Review of the literature].
Topics: Aged; Aged, 80 and over; Agranulocytosis; Dapsone; Female; Giant Cell Arteritis; Humans | 1988 |
15 other studies available for dapsone and Aortic Arteritis, Giant Cell
| Article | Year |
|---|---|
Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Biopsy; Dapsone; Drug Hypersensitivity; Drug Toleran | 2016 |
[Treatment of Horton's disease and rhizomelic pseudopolyarthritis with dapsone. Preliminary results].
Topics: Aged; Dapsone; Female; Giant Cell Arteritis; Humans; Male; Polymyalgia Rheumatica | 1983 |
[Dapsone in the treatment of Horton's disease].
Topics: Aged; Dapsone; Giant Cell Arteritis; Humans | 1983 |
[Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica].
Topics: Aged; Anemia, Hemolytic; Dapsone; Female; Follow-Up Studies; Giant Cell Arteritis; Humans; Iatrogeni | 1984 |
The use of dapsone in the treatment of giant cell arteritis and polymyalgia rheumatica.
Topics: Aged; Anti-Inflammatory Agents; Dapsone; Female; Giant Cell Arteritis; Humans; Male; Polymyalgia Rhe | 1983 |
[Value of dapsone in the treatment of Horton's disease and rhizomelic pseudopolyarthritis].
Topics: Aged; Dapsone; Female; Giant Cell Arteritis; Humans; Male; Polymyalgia Rheumatica; Prednisone | 1983 |
[Regressive trigeminal neuropathy under dapsone in temporal arteritis].
Topics: Aged; Dapsone; Female; Giant Cell Arteritis; Humans; Neuritis; Trigeminal Nerve | 1993 |
[Rhizomelic pseudopolyarthritis: diagnosis, course, treatment].
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; | 1999 |
[Granulomatous hepatitis caused by dapsone].
Topics: Adrenal Cortex Hormones; Aged; Chemical and Drug Induced Liver Injury; Dapsone; Drug Therapy, Combin | 1992 |
Dapsone in the long-term treatment of temporal arteritis.
Topics: Agranulocytosis; Dapsone; Giant Cell Arteritis; Humans | 1989 |
[Dapsone in rheumatology].
Topics: Arthritis, Rheumatoid; Dapsone; Giant Cell Arteritis; Humans; Polychondritis, Relapsing; Polymyalgia | 1986 |
[Prognosis of treated temporal arteritis. Retrospective study of 87 cases].
Topics: Aged; Chloroquine; Cyclophosphamide; Dapsone; Drug Therapy, Combination; Female; Giant Cell Arteriti | 1986 |
Dapsone in temporal arteritis and polymyalgia rheumatica.
Topics: Adult; Dapsone; Giant Cell Arteritis; Humans; Middle Aged; Polymyalgia Rheumatica | 1988 |
Long-term treatment of temporal arteritis with dapsone.
Topics: Aged; Dapsone; Giant Cell Arteritis; Humans; Male | 1988 |
[Disulon in the treatment of Horton's disease. Experience with 20 patients].
Topics: Aged; Aged, 80 and over; Dapsone; Drug Evaluation; Female; Giant Cell Arteritis; Humans; Male; Middl | 1986 |